)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Dyne Therapeutics (DYN) investor relations material
Dyne Therapeutics Evercore ISI 8th Annual HealthCONx Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Evercore ISI 8th Annual HealthCONx Conference summary2 Dec, 2025
Company overview and strategic direction
Focused on delivering functional improvement in neuromuscular diseases, specifically DMD and DM1.
Transitioning from early-stage to preparing for two product launches: DMD in early 2027, DM1 in early 2028.
Anticipates filing a BLA for DMD in Q2 next year; DM1 registrational cohort currently enrolling.
Management team and cash position support execution of these launches.
Clinical development and trial insights
DMD and DM1 trials use consistent inclusion-exclusion criteria; DMD cohort has 32 patients, DM1 has about 60.
Safety incidents in 2024 were unique and have not recurred; over 77 patient-years and nearly 1,000 doses administered.
Functional measures (NSAA, SV95C, time to rise, 10-meter walk-run) all showed improvement from baseline at six months.
Dystrophin levels in DMD study were significantly higher than historical approval benchmarks, with robust six-month data.
Dropout rates in trials have been low; all patients are crossing over into an open-label extension.
Regulatory and commercialization plans
Clear path for accelerated approval in the U.S.; phase 3 required for Europe, with plans to start by Q2 next year.
Pricing expected to be at least on par with current therapies (~$1M/year), with potential for premium based on functional data.
U.S. market opportunity includes rapid switching from existing therapies and re-engagement of patients who discontinued prior treatments.
Priority review voucher (PRV) is likely, with potential value around $150M.
Detail the strategy for capturing untreated DMD patients
How will functional data impact EU regulatory path?
Elaborate on CNS penetration's DM1 impact
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Dyne Therapeutics earnings date
Q4 202527 Feb, 2026
Next Dyne Therapeutics earnings date
Q4 202527 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Dyne Therapeutics Inc. is a biotechnology firm engaged in the development of innovative therapeutics aimed at addressing genetically driven muscle diseases. Established in 2017 and based in Waltham, Massachusetts, the company primarily focuses on advancing a portfolio of muscle disease therapeutics. These efforts include targeting conditions such as myotonic dystrophy type 1, duchenne muscular dystrophy, facioscapulohumeral dystrophy, and other rare skeletal, cardiac, and metabolic muscle diseases. Dyne Therapeutics utilizes its proprietary FORCE platform, which is designed to enhance the delivery of disease-modifying therapeutics directly to muscle tissue. Its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage